Journal article
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
M Dickinson, J Briones, AF Herrera, E González-Barca, N Ghosh, R Cordoba, SC Rutherford, E Bournazou, E Labriola-Tompkins, I Franjkovic, E Chesne, J Brouwer-Visser, K Lechner, B Brennan, E Nüesch, M DeMario, D Rüttinger, M Kornacker, M Hutchings
Blood Advances | Published : 2021
Abstract
Bromodomain and extraterminal (BET) proteins are transcriptional activators for multiple oncogenic processes in diffuse large B-cell lymphoma (DLBCL), including MYC, BCL2, E2F, and toll-like receptor signaling. We report results of a phase 1b dose-escalation study of the novel, subcutaneous BET inhibitor RO6870810 (RO) combined with the BCL-2 inhibitor venetoclax, and rituximab, in recurrent/refractory DLBCL. RO was delivered for 14 days of a 21-day cycle, whereas venetoclax was delivered continuously. A 313 escalation design was used to determine the safety of the RO1venetoclax doublet; rituximab was added in later cohorts. Thirtynine patients were treated with a median of 2.8 cycles (range..
View full abstractGrants
Funding Acknowledgements
The authors thank the patients, their families, and the study teams at the participating centers. Medical Writers Fiona Russel-Yarde (FRY Medical Communications Ltd.) and Christian Seitzprovided editorial assistance supported by funding from F. Hoffmann-La Roche Ltd. This study was sponsored and funded by F. Hoffmann-La Roche Ltd.